Additionally, iRhythm is expanding internationally, with early launches in Europe and plans to enter the Japanese market in mid-2025.

iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S

Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).